This FAERS analysis characterizes agent-specific safety profiles, informing pharmacovigilance strategies. Mechanistic profiling of adverse drug reactions optimizes evidence-based treatment, enhancing medication safety and refining benefit-risk profiles in clinical practice.

This case highlights the limited therapeutic efficacy of PRRT in RAIR-DTC, despite favorable imaging characteristics. It underscores the need for better patient selection and further research to clarify the role of PRRT in this population.

P3, N=338, Recruiting, RayzeBio, Inc. | Trial completion date: Jul 2028 --> Dec 2030

Age and weight did not show a clinically significant impact on 177Lu-DOTATATE exposure or kidney and bone marrow dosimetry values, confirming that flat dosing at adult dosage is appropriate for adolescents. 177Lu-DOTATATE with 7.4 GBq of activity, administered over 4 cycles 8 wk apart, is a well-tolerated therapeutic dosing regimen for adolescent patients with gastroenteropancreatic neuroendocrine tumors or pheochromocytomas and paragangliomas.

P1, N=10, Recruiting, University of Wisconsin, Madison | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

P1/2, N=16, Active, not recruiting, RayzeBio, Inc. | Recruiting --> Active, not recruiting | N=124 --> 16

P2/3, N=160, Recruiting, Philipps-Universitaet Marburg | Not yet recruiting --> Recruiting

P1, N=65, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jun 2026 --> Dec 2025

P1, N=31, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> Aug 2026 | Trial primary completion date: Jun 2027 --> Aug 2026

P2, N=32, Active, not recruiting, NYU Langone Health | Trial primary completion date: Jan 2026 --> Apr 2025

This Delphi consensus provides pragmatic, multidisciplinary, and evidence-informed guidance to harmonize routine clinical practice in the use of PRRT for well-differentiated, SSTR-positive NETs. The proposed statements and the algorithm aim to harmonize practice across centers, reduce variability in care, enhance safety, and ultimately improve patient outcomes.

We report a case of meningioma brain tumor becoming refractory after initial neurosurgery and stereotactic radiotherapy. Meningioma has progressed to lung metastases displaying high expression of SSTR, and hence suitable for PRRT.